What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Gene
His primary areas of investigation include Immunology, Dendritic cell, Cytotoxic T cell, Antigen and Antigen-presenting cell.
His research integrates issues of Cancer research, CD40, Bortezomib, Cell biology and Interleukin 10 in his study of Dendritic cell.
His biological study spans a wide range of topics, including Epitope, Molecular biology, Peripheral blood mononuclear cell and Major histocompatibility complex.
The study incorporates disciplines such as Virology, Immune system, Immunotherapy, Viral replication and Antigen presentation in addition to Antigen.
In the field of Immune system, his study on Lymphokine-activated killer cell overlaps with subjects such as Context.
The various areas that he examines in his Antigen-presenting cell study include Endocytic cycle, Endocytosis and Internalization.
His most cited work include:
- Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids. (642 citations)
- Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. (555 citations)
- Identification of HLA-A2–Restricted T-Cell Epitopes Derived From the MUC1 Tumor Antigen for Broadly Applicable Vaccine Therapies (370 citations)
What are the main themes of his work throughout his whole career to date?
Peter Brossart mainly investigates Internal medicine, Immunology, Cancer research, Oncology and Antigen.
His Internal medicine research is multidisciplinary, relying on both Gastroenterology and Surgery.
His study in Immunology concentrates on Immune system, Immunotherapy, Dendritic cell and T cell.
His Dendritic cell study combines topics in areas such as Cell biology, Monocyte and Antigen-presenting cell.
His research in Cancer research intersects with topics in Apoptosis and Pathology.
His study looks at the relationship between Antigen and topics such as Cytotoxic T cell, which overlap with Major histocompatibility complex.
He most often published in these fields:
- Internal medicine (34.18%)
- Immunology (29.10%)
- Cancer research (24.86%)
What were the highlights of his more recent work (between 2018-2021)?
- Internal medicine (34.18%)
- Oncology (19.77%)
- Cancer research (24.86%)
In recent papers he was focusing on the following fields of study:
His primary areas of investigation include Internal medicine, Oncology, Cancer research, Multiple myeloma and Nivolumab.
Internal medicine connects with themes related to Gastroenterology in his study.
The concepts of his Oncology study are interwoven with issues in Clinical trial, Long term results, Chemotherapy and Immunotherapy.
His Cancer research study incorporates themes from Acquired immune system, Oxidative stress, Methylation, DNA methylation and Dendritic cell.
His biological study deals with issues like White blood cell, which deal with fields such as T cell and Immune system.
In his study, Immunology and Cancer is strongly linked to Severe acute respiratory syndrome coronavirus 2, which falls under the umbrella field of T cell.
Between 2018 and 2021, his most popular works were:
- Nivolumab alone and with ipilimumab in previously treated metastatic urothelial carcinoma: CheckMate 032 nivolumab 1 mg/kg plus ipilimumab 3 mg/kg expansion cohort results (60 citations)
- Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use (40 citations)
- Antibiotic resistant bacteria and resistance genes in biofilms in clinical wastewater networks. (22 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Gene
His primary scientific interests are in Internal medicine, Oncology, Chemotherapy, Immunotherapy and DNA methylation.
His Internal medicine study frequently involves adjacent topics like Gastroenterology.
His studies deal with areas such as Clinical trial, Melphalan, Lenalidomide, Multiple myeloma and Randomized controlled trial as well as Oncology.
His Chemotherapy study integrates concerns from other disciplines, such as Nivolumab, Adverse effect and Carcinoma.
The DNA methylation study combines topics in areas such as Immune checkpoint, Cancer research and Methylation.
Peter Brossart studies Melanoma, a branch of Cancer research.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
